This longitudinal, observational study aims to assess whether the characteristics of a novel blood peripheral biomarker can serve as indicators for depression and schizophrenia in patients at the Royal Columbian Hospital Psychiatric Clinics. The study will evaluate whether changes in these biomarker characteristics can help distinguish between depressed patients who do or do not respond to treatment and between individuals experiencing a single psychotic episode and those at risk of progressing to schizophrenia. To achieve this, blood samples and standardized mental health assessments will be collected across three study visits from up to 500 participants, grouped into two study arms based on their diagnosis: Depression (DEP) or Psychosis/Schizophrenia (PSY).
Study Type
OBSERVATIONAL
Enrollment
500
Royal Columbian Hospital
New Westminster, British Columbia, Canada
Relationship between Depression and Biomarker Characteristics
In the DEP arm, the study will evaluate the relationship between depression diagnosis, antidepressant responsiveness (assessed through changes in a standardized mental health questionnaire over time), and the characteristics of a novel blood peripheral biomarker.
Time frame: 6 months from enrollment, across three study visits.
Relationship between Psychotic Disorders and Biomarker Characteristics
In the PSY arm, the study will evaluate the relationship between schizophrenia (defined as chronic, recurrent psychosis) and other psychotic disorders and the characteristics of a novel blood peripheral biomarker. A standardized clinical assessment tool will be used to support the diagnosis of schizophrenia.
Time frame: 6 months from enrollment, across 3 study visits.
Association between Clinical-Demographic Factors and Biomarker Characteristics.
In the DEP arm, the study will evaluate the relationship between a novel blood peripheral biomarker and various clinical and demographic factors. These factors include time, age, sex assigned at birth, and symptom severity related to suicidality, anxiety, substance use, and inflammation. Standardized mental health and clinical assessment tools will be used to quantify these variables.
Time frame: 6 months from enrollment, across 3 study visits.
Relationship between PSY arm Clinical-Demographic Factors and Biomarker Characteristics.
In the PSY arm, the study will evaluate the relationship between the characteristics of a novel blood peripheral biomarker and various clinical and demographic factors. These factors include time, age, sex assigned at birth, and symptom severity related to psychosis, suicidality, anxiety, substance use, and inflammation. Standardized mental health and clinical assessment tools will be used to quantify these variables.
Time frame: 6 months from enrollment, across 3 study visits.
Association between Psychotic Disorders Pharmacological Treatment and Biomarker Characteristics
In the PSY arm, the study will evaluate the relationship between changes over time in the characteristics of a novel blood peripheral biomarker and exposure to antipsychotics and other non-SSRI medications.
Time frame: 6 months from enrollment, across 3 study visits.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.